Ellipsis Health: Turning Everyday Conversations Into Early Warnings for Mental Health
What is Ellipsis Health? Ellipsis Health combines clinically validated vocal biomarkers (short voice recordings analysed by ML) with an enterprise AI care-manager called Sage to screen, monitor and autonomously engage patients at scale. The platform is designed for population screening, care-management call workflows, telehealth follow-ups and chronic-care outreach ā surfacing depression/anxiety signals, prioritising high-risk callers, […]
Feature Categories
What is Ellipsis Health?
Ellipsis Health combines clinically validated vocal biomarkers (short voice recordings analysed by ML) with an enterprise AI care-manager called Sage to screen, monitor and autonomously engage patients at scale. The platform is designed for population screening, care-management call workflows, telehealth follow-ups and chronic-care outreach ā surfacing depression/anxiety signals, prioritising high-risk callers, and escalating to human clinicians when needed.
Ellipsis positions its tech as a low-friction, privacy-guarded supplement to PHQ/GAD screening, enabling earlier detection and continuous monitoring while reducing administrative burden for health plans and systems.
Why Leading Healthcare Teams Trust Ellipsis Health
- Trusted by leading healthcare institutions and operates as a cloud-based solution that is highly scalable and platform agnostic
- Secured $45 million Series A funding led by Salesforce, Khosla Ventures, and CVS Health Ventures in 2025, demonstrating strong investor confidence
- Total funding of $75 million from tier-one investors including Vinod Khosla, Marc Benioff, ICONIQ Capital, and other prominent venture firms
- Uses voice as a biomarker to identify, measure, and monitor stress, anxiety, and depression at scale through natural speech analysis
- Provides objective clinical decision support tool through partnerships with providers, payers, and digital health companies
- Founded in 2017 with 39 total investors and operates in the highly regulated mental healthcare space
- Focuses specifically on mental health care utilizing voice biomarkers within the healthcare technology sector
- Recently launched Sage, their emotionally intelligent AI Care Manager product
Top 3 Pain Points Ellipsis Health Fixes in Healthcare
| Problem | How Ellipsis Health Solves It |
|---|---|
| 1. Missed or delayed detection of depression/anxiety | Uses AI voice biomarkers to identify mental-health signals early and continuously. |
| 2. Overburdened clinicians and care managers | Automates routine screening, triage, and follow-up calls, freeing clinicians for higher-value tasks. |
| 3. Gaps in population-level mental health monitoring | Scales across large patient groups, integrating into call centers and care-management workflows. |
Feature Category Summary: Ellipsis Health
| Feature Category | Summary | Association (YES, NO, NA) |
|---|---|---|
| Regulatory-Ready | Ellipsis Health highlights SOC 2 Type II, GDPR, and HIPAA compliance, and notes it is working toward HITRUST certification, but there is no mention of FDA or EMA clearance, 21 CFR Part 11/Annex 11 validation, or GxP auditātrail/CSV documentation; the tools are positioned as clinical decision support and careāmanagement aids, not as cleared medical devices.ā No public documentation found that the platform is validated as a regulatoryāready GxP/Partā11 system. | NA |
| Clinical Trial Support | Use cases focus on screening and monitoring mentalāhealth symptom severity, augmenting PHQā8/9 and GADā7, and automating outreach through Sage for enrollment, assessments, adherence checks, and postādischarge followāup.ā There is no indication of functionality for trial protocol design, subject recruitment logistics, trial endpoint monitoring, or submission reporting. | NA |
| Supply Chain & Quality | The platform analyzes speech to assess mental health and drive careāmanagement workflows; no capabilities are described for pharmaceutical manufacturing integrity, batch QA, serialization, or counterfeitāmedicine detection.ā No public documentation found for supplyāchain or manufacturingāquality support. | NA |
| Efficiency & Cost-Saving | Ellipsis positions Sage as an āemotionally intelligent AI care managerā that performs fully autonomous multilingual phone outreach for enrollment, assessments, coordination, and followāup, explicitly aiming to āimmediately expand capacity,ā āreduce costs,ā and āsupercharge existing workflowsā for providers, payers, and careāmanagement organizations.ā Research posts also emphasize that automated preāvisit screening and continuous voiceābased monitoring free cliniciansā time and make patient encounters more efficient.ā | YES |
| Scalable / Enterprise-Grade | Ellipsis describes its SaaS platform as HIPAA and SOC 2 Type II compliant with FHIRābased data standards and API availability, and customer lists include large organizations such as Highmark Health.ā Series A funding of $45M led by Salesforce, Khosla Ventures, and CVS Ventures is explicitly intended to scale Sage adoption across providers, payers, and careāmanagement organizations, indicating an enterpriseāgrade, healthcareāfocused deployment model (though not in pharma/biotech).ā | YES |
| HIPAA Compliant | Security materials state that Ellipsis Health adheres to HIPAA and SOC 2 Type II, with endātoāend encryption, regular thirdāparty security audits, and compliant handling of sensitive mentalāhealth data.ā Company descriptions reiterate āHIPAA and SOC2 Type 2 compliant infrastructureā as a core attribute of Sage, which is explicit evidence of HIPAAāaligned operation. | YES |
| Clinically Validated | Ellipsis repeatedly describes its voice biomarker as āclinically validated,ā citing peerāreviewed work, including an IEEE study showing the algorithm is a āviable techniqueā accepted by patients of different ages and races, and a feasibility study where the Ellipsis app successfully screened for depression and anxiety across age groups by comparing its scores with PHQā9 and GADā7.ā University of Denver and University of Michigan research partnerships are actively validating the tool in adolescents, directly comparing Ellipsis scores with standard questionnaires, reinforcing clinical validation for symptomāseverity assessment use.ā | YES |
| EHR Integration | Ellipsis states that its voiceābiomarker assessments can be embedded in telemedicine calls, digital front doors, and apps, and HealthAidb notes use of FHIR and APIābased integration into care workflows, but specific named EHR integrations (Epic, Cerner, etc.) are not detailed.ā No public documentation found that explicitly confirms direct integration with particular EHR vendors or ināEHR launch workflows. | NA |
| Explainable AI | Company materials mention ātransparent AI decisionāmaking processes,ā and research posts describe that the system analyzes both semantic content and acoustic features and compares voiceāderived scores with PHQ/GAD measures, but there is no description of endāuser features that expose model rationales, featureāimportance, or perāprediction explanations.ā Transparency is framed in general terms, not as concrete explainableāAI tooling accessible to clinicians. | NA |
| Real-Time Analytics | Ellipsis technology analyzes ā60āsecond voice recordings and can be ālayered seamlessly onto calls between a provider and a patient,ā enabling near realātime assessment of anxiety/depression severity during live interactions or routine checkāups.ā While processing is encounterābased rather than streaming physiologic data, it does provide onātheāfly symptomāseverity analytics within clinical workflows. | YES |
| Bias Detection | Ellipsis explicitly addresses bias: its safety and dataāprotection FAQ describes deliberate collection of hundreds of thousands of recordings from diverse demographics and asks, āHow does Ellipsis Health reduce biases in its AI models?ā, outlining steps to build representative datasets to avoid bias.ā Research notes that its large, diverse voice databases and peerāreviewed IEEE study show acceptance and performance across ages and races, which constitutes explicit biasāmitigation and monitoring at the data and modelāevaluation level, even if not exposed as a separate product module.ā | YES |
| Ethical Safeguards | Ellipsis repeatedly emphasizes privacy, consent, and data security āat the forefrontā, noting adherence to HIPAA, SOC 2, GDPR, and work toward HITRUST, alongside clinical oversight of all AI operations, continuous validation, and monitoring.ā Company statements and independent coverage stress that the tool does not provide a diagnosis, but supports clinicians by assessing symptom severity and augmenting PHQ/GAD surveys, keeping human clinicians in the loop and positioning Sage as assistive, not autonomous clinical decisionāmaker.ā | YES |
Risks & Limitations: Ellipsis Health
-
Audio quality & environment sensitivity: background noise, low-fidelity calls, and telephony compression reduce signal quality and diagnostic accuracy.
-
Population & language bias: acoustic and linguistic models may underperform on accents, dialects and languages not represented in training data ā local validation and re-calibration are essential.
-
Regulatory / clinical acceptance: voice-biomarker outputs are advisory; clinical adoption requires documented pathways, validation against local cohorts, and medico-legal clarity.
-
False positives & workflow burden: without tuned PPV thresholds, triage flags can overwhelm behavioural-health teams; set operational thresholds and volume caps in pilots.
Follow HealthyData.Science on Google Search & AI
Get our latest healthcare and life science AI tool evaluations, regulatory updates, and buyer intelligence in your Google AI Overviews.
Add as Preferred SourceGet a neutral, no obligation view of whether this AI tool fits your portfolio
